Deep Medicine Acquisition... (DMAQ)
Deep Medicine Acquisition Statistics
Share Statistics
Deep Medicine Acquisition has 4.36M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 4.36M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 501.86K |
| Failed to Deliver (FTD) Shares | 245 |
| FTD / Avg. Volume | 1.72% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -61.38 and the forward PE ratio is null. Deep Medicine Acquisition's PEG ratio is -0.2.
| PE Ratio | -61.38 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 9.62 |
| P/FCF Ratio | -23.7 |
| PEG Ratio | -0.2 |
Enterprise Valuation
Deep Medicine Acquisition has an Enterprise Value (EV) of 25.84M.
| EV / Sales | 0 |
| EV / EBITDA | -6.47 |
| EV / EBIT | -24.93 |
| EV / FCF | -24.93 |
Financial Position
The company has a current ratio of 3.5, with a Debt / Equity ratio of 0.73.
| Current Ratio | 3.5 |
| Quick Ratio | 3.5 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | -0.47 |
| Debt / FCF | -1.8 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -15.67% and Return on Invested Capital is -9.06%.
| Return on Equity | -15.67% |
| Return on Assets | -4.09% |
| Return on Invested Capital | -9.06% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-200.12K |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 57.57K |
| Effective Tax Rate | -16.8% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0.02, so Deep Medicine Acquisition's price volatility has been higher than the market average.
| Beta | 0.02 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 10.76 |
| 200-Day Moving Average | 11.2 |
| Relative Strength Index (RSI) | 15.43 |
| Average Volume (20 Days) | 14.21K |
Income Statement
| Revenue | n/a |
| Gross Profit | -60K |
| Operating Income | -342.66K |
| Net Income | -400.23K |
| EBITDA | -3.99M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.17 |
Balance Sheet
The company has 595.54K in cash and 1.86M in debt, giving a net cash position of -1.27M.
| Cash & Cash Equivalents | 595.54K |
| Total Debt | 1.86M |
| Net Cash | -1.27M |
| Retained Earnings | -6.44M |
| Total Assets | 6.88M |
| Working Capital | 3.18M |
Cash Flow
In the last 12 months, operating cash flow was -1.04M and capital expenditures 0, giving a free cash flow of -1.04M.
| Operating Cash Flow | -1.04M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.04M |
| FCF Per Share | -0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.63% |
| FCF Yield | -4.22% |
Analyst Forecast
Currently there are no analyst rating for DMAQ.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.19 |
| Piotroski F-Score | 3 |